Comparing the current results to its competitors, Rigel Pharmaceuticals Inc reported Revenue decrease in the 2 quarter 2026 year on year by -22.6 %, faster than the overall decrease of Rigel Pharmaceuticals Inc's competitors by -12.95 %, recorded in the same quarter.
Publicly Traded Peers of Rigel Pharmaceuticals Inc
Blueprint Medicines Corporation Share Performance
+50.91%
This Quarter
Blueprint Medicines Corporation
Profile
The business model of Blueprint Medicines Corporation revolves around the development and commercialization of precision therapies for patients with genomically defined cancers and rare diseases. They actively pursue a strategy of genomically targeted drug discovery and development, utilizing advanced technologies and clinical expertise to bring potentially life-changing treatments to market. The company focuses on creating value through strategic collaborations, licensing agreements, and the commercialization of their innovative therapies.
Creative Medical Technology Holdings Inc Share Performance
-67.45%
One Year
Creative Medical Technology Holdings Inc
Profile
Creative Medical Technology Holdings Inc is a biotechnology company that focuses on developing and commercializing regenerative medical treatments utilizing stem cell technology and tissue engineering. Their business model involves research, development, and licensing of cutting-edge therapies to address various medical conditions.
Essa Pharma Inc.'s business model revolves around the development of targeted small molecule therapeutics for the treatment of cancer. The company aims to address the unmet medical needs of patients with advanced and metastatic forms of prostate and breast cancer. By leveraging their expertise in clinical development and precision medicine, Essa Pharma aspires to bring innovative and effective treatments to market, ultimately improving patient outcomes.
Erasca Inc is a biotechnology company that focuses on discovering and developing innovative therapies for cancer. Their business model revolves around leveraging cutting-edge technologies and scientific expertise to identify and advance multiple drug candidates simultaneously. By collaborating with academic institutions and biopharmaceutical partners, Erasca aims to accelerate the development of cancer treatments to improve patient outcomes.
Hutchmed China Limited operates on a vertically integrated platform, focusing on the discovery, development, and commercialization of targeted therapeutics for oncology and immunological diseases. The company employs a comprehensive business model that encompasses research and development, manufacturing, marketing, and sales in order to deliver innovative drugs to patients. By leveraging its internal capabilities and strategic partnerships, Hutchmed China aims to transform the treatment landscape and improve the lives of patients in China and around the world.
Sources:
Rigel Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Rigel Pharmaceuticals Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
